<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082599</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 2016-002</org_study_id>
    <nct_id>NCT03082599</nct_id>
  </id_info>
  <brief_title>Symfony Toric Intraocular Lens Visual Outcomes</brief_title>
  <official_title>Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolina Eyecare Physicians, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Science in Vision</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Carolina Eyecare Physicians, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In July 2016, the FDA approved an extended depth of focus (EDOF) IOL (Tecnis Symfony, Abbott
      Medical Optics) helping to improve the sharpness of vision at near, intermediate and far
      distances reducing the need of glasses after cataract surgery. It is available in both a
      non-toric version and a toric version for patients with astigmatism. The difference between
      this lens and the multifocal (MIOL) counterpart is that the EDOF, similarly to a monofocal
      IOL, has one focal point (elongated in the EDOF) while the multifocals have 2 focal points;
      therefore, having less of a halo and glare problem. Pivotal trial results where Symfony was
      compared to a monofocal IOL showed similar uncorrected distance visual acuity (UCDVA), better
      intermediate (77% vs. 34% 20/25 uncorrected intermediate visual acuity - UCIVA) and near
      vision (Symfony patients were able to read two additional, progressively smaller lines
      compared to the monofocal IOL).A One potential disadvantage of the EDOF IOL compared to a
      MIOL is the visual performance at near.B One option to deal with this potential shortcoming
      is to set the non-dominant eye for a small residual myopic error (-0.50 D)C what is referred
      to as nano-vision or mini mono-vision.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Actual">April 3, 2018</completion_date>
  <primary_completion_date type="Actual">April 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binocular Distance-corrected Near (40 cm) Visual Acuity.</measure>
    <time_frame>3 months</time_frame>
    <description>Visual acuity with correction (glasses) measured at 40 cm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of Manifest Cylinder (Diopters).</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Near (40 cm) Visual Acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Visual acuity without correction (no glasses) measured at 40 cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Intermediate (66 cm) Visual Acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Visual acuity without correction (no glasses) measured at 66 cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected (4 m) Visual Acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Visual acuity without correction (no glasses) measured at 4 m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Patient-Reported Visual Symptoms Questionnaire (PRVSQ)</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of patients who reported any visual symptoms such as halos, glare, starburst, light sensitivity when answering the self administered questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Spectacle Independence Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of participants who reported wearing glasses none or a little of the time in the self administered questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Residual Mean Spherical Equivalent Refraction</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Residual Refractive Sphere</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Residual Refractive Cylinder</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Eyes With Postoperative Manifest Refraction Spherical Equivalent (MRSE) Accuracy to Target ≤ 0.5D</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Cataract Bilateral</condition>
  <condition>Astigmatism Bilateral</condition>
  <arm_group>
    <arm_group_label>Emmetropia both eyes (OU) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nanovision group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Presbyopia and astigmatism correcting intraocular lens</intervention_name>
    <description>The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
    <arm_group_label>Emmetropia both eyes (OU) group</arm_group_label>
    <arm_group_label>Nanovision group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is undergoing bilateral cataract extraction with intraocular lens
             implantation.

          2. Willing and able to provide written informed consent for participation in the study

          3. Willing and able to comply with scheduled visits and other study procedures.

          4. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes
             within 6-15 days between surgeries.

          5. Subjects who require an IOL power in the range of +5.0 D to +34.0 D only.

          6. Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both
             eyes.

        Exclusion Criteria:

          1. Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative
             diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment,
             aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization,
             medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve
             atrophy, macular degeneration (with anticipated best postoperative visual acuity less
             than 20/30), advanced glaucomatous damage, etc.

          2. Uncontrolled diabetes.

          3. Use of any systemic or topical drug known to interfere with visual performance.

          4. Contact lens use during the active treatment portion of the trial.

          5. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.

          6. Clinically significant corneal dystrophy

          7. History of chronic intraocular inflammation.

          8. History of retinal detachment.

          9. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the
             zonules.

         10. Previous intraocular surgery.

         11. Previous refractive surgery.

         12. Previous keratoplasty

         13. Severe dry eye

         14. Pupil abnormalities

         15. Subject who may reasonably be expected to require a secondary surgical intervention at
             any time during the study (other than yttrium aluminum garnet (YAG) capsulotomy, i.e.
             LASIK)

         16. Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).

         17. Any clinically significant, serious or severe medical or psychiatric condition that
             may increase the risk associated with study participation or may interfere with the
             interpretation of study results.

         18. Participation in (or current participation) any ophthalmic investigational drug or
             ophthalmic device trial within the previous 30 days prior to the start date of this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry D. Solomon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Carolina Eyecare Physicians, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associated Eye Care</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Eyecare Physicians, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slade &amp; Baker Vision Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <results_first_submitted>January 30, 2019</results_first_submitted>
  <results_first_submitted_qc>January 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03082599/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 120 patients were enrolled and randomized; however, data from only 79 patients was analyzed due to major procedural issues at one site. One patient in the Emmetropia group missed the 3-month visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Emmetropia Both Eyes (OU) Group</title>
          <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
        </group>
        <group group_id="P2">
          <title>Nanovision Group</title>
          <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Emmetropia Both Eyes (OU) Group</title>
          <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
        </group>
        <group group_id="B2">
          <title>Nanovision Group</title>
          <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="7.1"/>
                    <measurement group_id="B2" value="69.0" spread="9.3"/>
                    <measurement group_id="B3" value="68.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Binocular Distance-corrected Near (40 cm) Visual Acuity.</title>
        <description>Visual acuity with correction (glasses) measured at 40 cm.</description>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Binocular Distance-corrected Near (40 cm) Visual Acuity.</title>
          <description>Visual acuity with correction (glasses) measured at 40 cm.</description>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.14"/>
                    <measurement group_id="O2" value="0.26" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Manifest Cylinder (Diopters).</title>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Manifest Cylinder (Diopters).</title>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.77"/>
                    <measurement group_id="O2" value="1.38" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Near (40 cm) Visual Acuity</title>
        <description>Visual acuity without correction (no glasses) measured at 40 cm.</description>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Near (40 cm) Visual Acuity</title>
          <description>Visual acuity without correction (no glasses) measured at 40 cm.</description>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.12"/>
                    <measurement group_id="O2" value="0.19" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Intermediate (66 cm) Visual Acuity</title>
        <description>Visual acuity without correction (no glasses) measured at 66 cm.</description>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Intermediate (66 cm) Visual Acuity</title>
          <description>Visual acuity without correction (no glasses) measured at 66 cm.</description>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.10"/>
                    <measurement group_id="O2" value="0.04" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected (4 m) Visual Acuity</title>
        <description>Visual acuity without correction (no glasses) measured at 4 m.</description>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected (4 m) Visual Acuity</title>
          <description>Visual acuity without correction (no glasses) measured at 4 m.</description>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.08"/>
                    <measurement group_id="O2" value="-0.02" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Patient-Reported Visual Symptoms Questionnaire (PRVSQ)</title>
        <description>Percentage of patients who reported any visual symptoms such as halos, glare, starburst, light sensitivity when answering the self administered questionnaire.</description>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Patient-Reported Visual Symptoms Questionnaire (PRVSQ)</title>
          <description>Percentage of patients who reported any visual symptoms such as halos, glare, starburst, light sensitivity when answering the self administered questionnaire.</description>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Spectacle Independence Questionnaire</title>
        <description>Percentage of participants who reported wearing glasses none or a little of the time in the self administered questionnaire.</description>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Spectacle Independence Questionnaire</title>
          <description>Percentage of participants who reported wearing glasses none or a little of the time in the self administered questionnaire.</description>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8"/>
                    <measurement group_id="O2" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Residual Mean Spherical Equivalent Refraction</title>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Mean Spherical Equivalent Refraction</title>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.22"/>
                    <measurement group_id="O2" value="-0.33" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Residual Refractive Sphere</title>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Refractive Sphere</title>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.20"/>
                    <measurement group_id="O2" value="-0.48" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Residual Refractive Cylinder</title>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Refractive Cylinder</title>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>diopters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.25"/>
                    <measurement group_id="O2" value="0.29" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Eyes With Postoperative Manifest Refraction Spherical Equivalent (MRSE) Accuracy to Target ≤ 0.5D</title>
        <time_frame>3 months</time_frame>
        <population>One subject in the emmetropia group missed the Month 3 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Emmetropia Both Eyes (OU) Group</title>
            <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
          <group group_id="O2">
            <title>Nanovision Group</title>
            <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Postoperative Manifest Refraction Spherical Equivalent (MRSE) Accuracy to Target ≤ 0.5D</title>
          <population>One subject in the emmetropia group missed the Month 3 visit.</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Average 3 months. Adverse events were collected from the moment patient enrolled in the study until exit.</time_frame>
      <desc>Only eye related events were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Emmetropia Both Eyes (OU) Group</title>
          <description>Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
        </group>
        <group group_id="E2">
          <title>Nanovision Group</title>
          <description>Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
Presbyopia and astigmatism correcting intraocular lens: The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Helga P Sandoval, Director of Research</name_or_title>
      <organization>Carolina Eyecare Physicians, LLC</organization>
      <phone>8438813937</phone>
      <email>helga.sandoval@carolinaeyecare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

